AI assistant
RENT.COM.AU LIMITED — Capital/Financing Update 2005
Nov 21, 2005
65722_rns_2005-11-21_ec2727d0-8253-4cc1-a488-d4875d0655fd.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer

Suite 1, 261 Wattletree Rd. Malvern Victoria 3144 Australia
$ASX$ RELEASE $-22$ November 2005
Telephone +613 8508 8201 Facsimile +613 9576 3055 www.selectvaccines.com.au.
PROPOSED PRO-RATA SHARE ISSUE
Select Vaccines Limited (ASX:SLT, "the Company") announces that it proposes to make an offer to existing shareholders of an opportunity to participate in a non-renounceable pro-rata issue of one share for every four fully paid shares held in the issued capital of the Company ("the Offer").
The Offer will be made to existing shareholders of the Company pursuant to a special prospectus for continuously quoted securities (s713 Corporations Act). Details of the Offer include:
- shareholders registered at the record date as described in the prospectus will have the opportunity to acquire one share for every four fully paid shares held in the issued capital of the Company:
- a proposed issue price of \$0.16 (16 cents) for each share; and
- each share allotted will rank equally with other ordinary shares in the issued capital of the Company.
- The issue is fully underwritten by Taylor Collison Limited and will raise up to \$1.73m (before costs).
- In addition to the pro-rata issues of shares, Taylor Collison will also place with their clients up to 3.75m shares at the same price of \$0.16 per share. Those issued with these shares will not be entitled to participate in the pro rata offer. This placement will raise up to \$600,000 if all shares are placed. The Company will not seek shareholder approval for this placement. Taylor Collison will place the shares to no more than twenty private investors
The purpose of the Offer is to provide working capital for the ongoing funding of the Company's projects and administrative costs including the advancement of new and existing projects, in particular the development of a vaccine against hepatitis C and further development of diagnostic assays. The Company will not seek shareholder approval in respect of the Offer.
The proposed timetable for the Offer:
| Lodgement of Prospectus with ASIC | 22 November 2005 |
|---|---|
| Record Date | 1 December 2005 |
| Acceptances close 5.00pm [AEST] (Unless closed earlier if permitted by the Listing Rules of ASX, or extended by Directors at their discretion or as may be required under the Corporations Act 2001) |
19 December 2005 |
| Allotment of New Shares | 22 December 2005 |
| Normal trading of New Shares commences on ASX (under ASX Code SLT) | 23 December 2005 |
The above dates are indicative only and may change. Subject to the requirements of the Corporations Act and the ASX Listing Rules, the Company reserves the right to extend the closing date or to close the offer early.
Dr Martin Soust Managing Director